Many past antitumor agents have predominately operated as non-specific cytotoxic tubulin inhibitors that, while successful have suffered from numerous drawbacks stemming from this non-specificity. Modern antitumor agents such as imatinib and regorafenib sought to improve upon these limitations by functioning as targeted kinase inhibitors and have improved side effect profiles and pose less hazards than tubulin inhibitors. Thalidomide and pomalidomide have recently been shown to possess antitumor activities through its vascular endothelial growth factor (VEGF) inhibition. TCI provides high quality pharmaceutical reagents for investigate research and biomedical applications.

**References**


2) R. Capdeville, E. Buchdunger, J. Zimmermann, A. Matter, *Nat. Rev. Drug Discovery* **2002**, *1*, 493. [http://dx.doi.org/10.1038/nrd839](http://dx.doi.org/10.1038/nrd839)


More references can be found on the application page for each product on TCI website.